Monday, December 18, 1995
Canji: The lure of core
For some time, the idealized relationship between the pharmaceutical and biotech
sectors has been one in which the pharma side accesses biotech products and expertise
through corporate partnerships that maintain the independence of the biotech companies.
That probably remains true for product-type deals. But the growing number of biotech
acquisitions indicates that in core technologies, such as screening, combinatorial
chemistry and gene therapy, many pharmaceutical companies prefer outright ownership.